Clinical Report: Efficacy of Low-Dose SGLT2 Inhibitors in Heart Failure Patients
Overview
This study evaluates the efficacy and safety of low-dose (5 mg) SGLT2 inhibitors in heart failure patients with diabetes. The analysis utilized a large nationwide cohort, revealing significant outcomes in reducing cardiac events and all-cause mortality.
Background
SGLT2 inhibitors are integral to heart failure management, particularly in patients with diabetes. Despite their established benefits, the optimal dosing for heart failure treatment remains uncertain, as prior studies have predominantly focused on higher doses.
Data Highlights
Group
Primary Outcome Hazard Ratio (HR)
All-Cause Death HR
5 mg
0.73 (95% CI: 0.66–0.81; P < 0.001)
0.85 (95% CI: 0.74–0.97; P = 0.019)
10 mg
0.67 (95% CI: 0.60–0.75; P < 0.001)
0.80 (95% CI: 0.69–0.93; P = 0.005)
Non-users
1.00 (Reference)
1.00 (Reference)
Key Findings
The 5 mg SGLT2i group showed a lower risk of the primary outcome compared to the 10 mg group.
5 mg SGLT2i was associated with a reduced risk of all-cause death compared to the 10 mg group.
Safety profiles for both doses were similar, indicating no increased risk of adverse effects.
Significant interactions were noted based on sex, body weight, and BMI affecting outcomes.
Sensitivity analyses confirmed consistent results across multiple time points.
Clinical Implications
Clinicians should consider individual patient characteristics when prescribing SGLT2 inhibitors.
Conclusion
The study supports the efficacy of low-dose SGLT2 inhibitors in heart failure patients with diabetes.
Related Resources & Content
Author(s)/Org, Source, Year -- Title
Frontiers in Cardiovascular Medicine, 2026 -- Efficacy of SGLT2 inhibitors in Patients Recently Hospitalized for Heart Failure
Frontiers in Cardiovascular Medicine, 2026 -- Long-term efficacy and renal safety of SGLT2 inhibitors in patients with heart failure and advanced chronic kidney disease
Nature Medicine, 2026 -- Effects of SGLT2 inhibition on incident heart failure in carriers of cardiomyopathy-associated genetic variants
2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction, JACC
SGLT2 Inhibitors for the Prevention and Treatment of Heart Failure
Dapagliflozin in Patients Hospitalized for Heart Failure
2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee | JACC
Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction - American College of Cardiology
JARDIANCE (empagliflozin tablets) Highlights of Prescribing Information
Effects of SGLT2 Inhibitors on Clinical Outcomes, Symptoms, Functional Capacity, and Cardiac Remodeling in Heart Failure: A Comprehensive Systematic Review and Multidomain Meta-Analysis of Randomized Trials - PMC
Efficacy of Ertugliflozin on Heart Failure–Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial - PMC
A structured overview of recent FDA recalls, corrections, and alerts involving medications, ventilators, insulin delivery systems, cardiovascular devices, anesthesia products, and other equipment used in clinical practice.
A single-center editorial described real-world integration of artificial intelligence–based coronary artery calcium scoring into routine cardiac CT workflow, with researchers reporting rapid report availability and high agreement with manual reference standards while emphasizing continued radiologist oversight.
